Clinical Trial Update: Efficacy, Safety and Pharmacokinetics of BI 655066/ABBV-066 (Risankizumab) in Patients With Active, Moderate-to-severe Crohn's Disease. [Phase 2]

View source ↗

Summary

Phase 2 trial update on risankizumab (BI 655066/ABBV-066) for active moderate-to-severe Crohn's disease evaluating efficacy, safety, and pharmacokinetics has co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Risankizumab (risankizumab)

Snippet

Sponsor: AbbVie | Conditions: Crohn Disease | Phase 2 | Status: COMPLETED | Results posted: 2018-11-23